NCT04620187 2026-04-13Post-op T-DM1 in HER-2+ Salivary Gland CarcinomasDana-Farber Cancer InstitutePhase 2 Recruiting37 enrolled
NCT04704661 2026-04-13Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialNational Cancer Institute (NCI)Phase 1 Recruiting51 enrolled
NCT06695845 2026-04-09A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsJazz PharmaceuticalsPhase 2 Recruiting200 enrolled
NCT05408845 2026-04-03Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland CancersNRG OncologyPhase 2 Recruiting146 enrolled
NCT05483374 2026-04-03EURACANFondazione IRCCS Istituto Nazionale dei Tumori, MilanoRecruiting13,600 enrolled
NCT06145308 2026-04-02Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingPeking Union Medical CollegePhase 2 Recruiting39 enrolled